Drug Trial Radar · NCT06970106
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Sep 30, 2025
Primary completion
Oct 2029
Study completion Nov 2029
Sponsor
- Lead sponsor
- PYC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to gather safety data and determine the optimal dosing regimen for PYC-001 in participants with confirmed OPA1 mutation-associated ADOA. Approximately 18 participants from Australia, New Zealand, and other APAC countries are expected to be enrolled, depending on safety review committee (SRC) throughout the course of the study. Participants may be assigned to any of the following: 1. A single 60ug dose of PYC-001 2. Three doses of 10ug PYC-001 at an interval of 8 weeks 3. Three doses of 10ug PYC-001 at an interval of 12 weeks 4. Three doses of 30ug PYC-001 at an interval of 8 weeks 5. Three doses of 30ug PYC-001 at an interval of 12 weeks Following completion of the 4 week safety review of the single 60ug of PYC-001 cohort, and if the 60 μg dose level is deemed safe by the SRC, the following cohorts will also be available: 6. Three doses of 60ug PYC-001 at an interval of 12 weeks
Conditions
- OPA1 Gene Mutation
- Autosomal Dominant Optic Atrophy
- Hereditary Optic Atrophies
- Kjer Optic Atrophy
Interventions
PYC-001Drug
PYC-001 is a peptide-phosphorodiamidate morpholino oligonucleotide administered intravitreally
Primary outcomes
What the sponsor says the trial is designed to measure.
- [All Cohorts] Number of participants experiencing treatment emergent adverse eventsTime frame: Up to 164 weeks
- [All Cohorts] Changes from baseline in vital signs (heart rate)Time frame: Up to 164 weeks
- [All Cohorts] Changes from baseline in vital signs (systolic and diastolic blood pressure)Time frame: Up to 164 weeks
- [All Cohorts] Changes from baseline in vital signs (tympanic temperature)Time frame: Up to 164 weeks
- [All Cohorts] Changes from baseline in vital signs (respiratory rate)Time frame: Up to 164 weeks
- [All Cohorts] Change from baseline in white blood cells (WBC), platelets, white blood cell count with differential neutrophil count, eosinophil count, basophil count, lymphocyte count, monocyte countTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in red blood cellsTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in hemoglobin and mean corpuscular hemaglobin concentrationTime frame: Up to164 weeks
- [All Cohorts] Change from baseline in mean corpuscular volume and mean platelet volumeTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in hematocritTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in mean corpuscular hemoglobinTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in neutrophils, lymphocytes, monocytes, eosinophils, basophils and reticulocyte countTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in Alanine Transaminase, Alkaline Phosphatase, Aspartate aminotransferase, Creatine Phosphokinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase, Amylase and LipaseTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in Bilirubin (total, direct and indirect) and creatinineTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in protein, albumin, globulin and fibrinogenTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Bicarbonate, Calcium, Magnesium, Phosphorous, Total Cholesterol, Triglyceride, HDL, LD. Uric Acid and GlucoseTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in Anion GapTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in Estimated Glomerular Filtration Rate (eGFR)Time frame: Up to 164 weeks
- [All Cohorts] Change from baseline in Prothrombin Time and Partial Thromboplastin Time, Activated (APTT)Time frame: Up to 164 weeks
- [All Cohorts] Change from baseline in Prothrombin Time (INR)Time frame: Up to 164 weeks
- [All Cohorts] Change from baseline in urinalysis (Protein, glucose, ketones, blood, bilirubin, leucocyte esterase and nitritesTime frame: Up to 164 weeks
- [All Cohorts] Change from baseline in urinalysis (pH)Time frame: Up to 164 weeks
- [All Cohorts] Change from baseline in urinalysis (specific gravity)Time frame: Up to 164 weeks
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Cerulea Clinical Trials
East Melbourne, Australia · Recruiting
Save Sight Institute - Sydney Eye Hospital
Sydney, New South Wales, Australia · Recruiting
Retina Specialists
Auckland, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.